Skip to main content

Drug Safety

      Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients?

      V
      Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients? VS placebo, PMR patients who received Clofutriben + Prednisone had substantial reductions in bone, lipid, and glycemic control parameters @RheumNow #ACR24
      Does vasculitis flare with checkpoint inhibitors?

      @MDAndersonNews experience:
      17 stable pts
      4 pts flared - all able to
      1 month ago
      Does vasculitis flare with checkpoint inhibitors? @MDAndersonNews experience: 17 stable pts 4 pts flared - all able to be controlled (i.e. 13 didn't flare) Encouragement that stable vasculitis pts that need ICI should get them! #ACR24 ABST1986 @RheumNow https://t.co/jO4w3HWBMd
      Risks for HCQ cardiotoxicity:
      👉>5 yrs use
      👉>5 mg/kg/d (cumulative dose >500,000 mg)
      👉CKD
      👉use NSA
      1 month ago
      Risks for HCQ cardiotoxicity: 👉>5 yrs use 👉>5 mg/kg/d (cumulative dose >500,000 mg) 👉CKD 👉use NSAID 👉preexisting heart dz 👉presence of ocular, derm, SkM toxicity - Dr M Garschik #ACR24 @rheumnow https://t.co/LFobgls4jm
      Dr. @karen_kc123 discusses the results of the VITAL study.
      - Long term use of Vit D3 2000IU was safe and decreased the i
      1 month ago
      Dr. @karen_kc123 discusses the results of the VITAL study. - Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%. - It took a while to work but the effect dissipates once discontinued. @RheumNow #ACR24 @rheumarhyme https://t.co/mnwRsdZ06N
      Study of 25K+ patients using TrinetX on immune checkpoint inhibitors shows no significant mortality difference between t
      Study of 25K+ patients using TrinetX on immune checkpoint inhibitors shows no significant mortality difference between those with pre-existing autoimmune disease (AID) and those without. Mortality rates: AID: 39.8% Non-AID: 40.2% Large-scale evidence supports ICIs in AID… https://t.co/BI5jK9jsoM
      A#2532
      Pre-existing AID for immunoRx?
      Excluded from trials
      4 prior studies showed no diff in mortality w AID
      Propensity-
      1 month ago
      A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6
      Treating SpA
      In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #S
      1 month ago
      In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE @RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd
      ×